Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Primary Breast Cancer|Her2 Non-overexpressing
Interventions: DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Cyclophosphamide|DRUG: Docetaxel
Sponsor: West German Study Group
Collaborators: Sanofi|Amgen